BUSINESS

Otsuka’s 9-Month Pharma Sales Up 0.8% on Double-Digit Growth of 4 Global Brands

November 16, 2021
Otsuka Holdings saw its pharma business sales inch up 0.8% over the previous year to 721 billion yen in the first nine months of 2021 on the back of robust performances delivered by four global brands, according to its earnings…

To read the full story

Related Article

BUSINESS

Japan’s health ministry on November 16 approved AbbVie’s glabellar lines drug Boey (trenibotulinumtoxinE), along with a slate of label expansions…

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…